Nigeria's National Agency for the Control of AIDS (NACA) announced that the country will receive shipments of Lenacapavir, a new injectable drug for HIV prevention, starting in March 2026. This drug is designed to be administered twice a year, marking a significant development in the country's public health strategy against HIV. The announcement coincides with the completion of readiness assessments in ten states, including major population centers, to ensure the effective implementation of this pre-exposure prophylaxis (PrEP) initiative.

The government's commitment to strengthening HIV prevention is evident in its proactive measures to prepare for the introduction of Lenacapavir. These preparations include evaluating service delivery capacities in regions such as Akwa Ibom, Anambra, and Lagos, which are vital for successful health interventions. NACA emphasizes the importance of addressing local needs and ensuring that the healthcare infrastructure can support this new treatment option.

By rolling out Lenacapavir, Nigeria aims to accelerate progress toward epidemic control and reduce new HIV infections, which remain a significant public health issue in the country. The introduction of a twice-yearly injection could improve adherence to preventive measures and provide a more effective option for populations at high risk of HIV. This move is part of a broader strategy to enhance national health outcomes and support those affected by HIV/AIDS in Nigeria.